Immunovant (IMVT) EBITDA (2018 - 2026)
Immunovant (IMVT) posted EBITDA of -$150.4 million for Q1 2026, down 1952.81% on a QoQ basis from $8.1 million in Q4 2025, and down 233.22% year-over-year from $112.9 million in Q1 2025.
Immunovant (IMVT) EBITDA (2018 - 2026) Analysis & Trends
Immunovant's EBITDA history runs 9 years deep, the most recent figure standing at -$150.4 million for Q1 2026.
- Quarterly EBITDA fell 233.22% year-over-year to -$150.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$266.0 million (down 160.93% YoY) and the FY2026 annual result came in at -$193.4 million, changed 0.39% from the prior year.
- EBITDA was -$150.4 million for Q1 2026 at Immunovant, down from $8.1 million in the prior quarter.
- Across five years, EBITDA topped out at $377.9 million in Q4 2023 and bottomed at -$150.4 million in Q1 2026.
- A 5-year average of $43.0 million and a median of $8.1 million in 2025 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2023 — EBITDA surged 834.06% — and 2026, when it slumped 233.22%.
- Immunovant's EBITDA stood at $51.7 million in 2022, then soared by 630.49% to $377.9 million in 2023, then sank by 82.02% to $67.9 million in 2024, then sank by 88.05% to $8.1 million in 2025, then slumped by 1952.81% to -$150.4 million in 2026.
- Business Quant data shows IMVT's EBITDA at -$150.4 million in Q1 2026, $8.1 million in Q4 2025, and -$77.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Immunovant | 7.17 Bn | 7.17 Bn | - | -150.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -150.45 Mn |
| Dec 31, 2025 | 8.12 Mn |
| Sep 30, 2025 | -77.82 Mn |
| Jun 30, 2025 | -45.89 Mn |
| Mar 31, 2025 | 112.93 Mn |
| Dec 31, 2024 | 67.93 Mn |
| Sep 30, 2024 | 126.04 Mn |
| Jun 30, 2024 | 129.69 Mn |
| Mar 31, 2024 | -71.72 Mn |
| Dec 31, 2023 | 377.91 Mn |
| Sep 30, 2023 | 332.87 Mn |
| Jun 30, 2023 | 60.33 Mn |
| Mar 31, 2023 | -58.38 Mn |
| Dec 31, 2022 | 51.73 Mn |
| Sep 30, 2022 | -45.35 Mn |
| Jun 30, 2022 | -40.01 Mn |
| Mar 31, 2022 | -46.96 Mn |
| Dec 31, 2021 | -39.75 Mn |
| Sep 30, 2021 | -35.42 Mn |
| Jun 30, 2021 | -22.37 Mn |